山东亚华电子股份有限公司 第四届监事会第四次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 山东亚华电子股份有限公司（以下简称"公司"）第四届监事会第四次会 议于 2025 年 7 月 16 日（星期三）在公司会议室以现场结合通讯的方式召开。会 议通知已于 2025 年 7 月 15 日通过邮件等方式送达各位监事，全体监事一致同意 豁免本次会议通知时间要求。本次会议应出席监事 3 人，实际出席监事 3 人（其 中荆凯监事以通讯方式出席）。 证券代码：301337 证券简称：亚华电子 公告编号：2025-027 表决结果：3 票同意，0 票反对，0 票弃权。 本议案需提交公司 2025 年第二次临时股东大会审议,并需由经出席股东大会 的股东所持有表决权的三分之二以上表决通过。 （二）审议通过《关于与关联方共同投资设立控股子公司暨关联交易的议 案》 监事会认为：公司及白泽超越与关联方共同投资设立控股子公司，有利于进 一步开拓海外市场，对公司长期发展具有积极影响。本次交易事项的审议及表决 程序符合相关法律、法规的规定，交易遵循自 ...

山东亚华电子股份有限公司（以下简称"公司"）第四届董事会第四次会议 于 2025 年 7 月 16 日（星期三）在公司会议室以现场结合通讯的方式召开。会议 通知已于 2025 年 7 月 15 日通过邮件等方式送达各位董事，全体董事一致同意豁 免本次会议通知时间要求。本次会议应出席董事 7 人，实际出席董事 7 人（其中 向晖、宋庆、张国华、吴忠堂、赵毅新、罗治洪董事以通讯方式出席）。 会议由董事长耿斌主持，董事会秘书、财务总监于雷，第四届董事会非独立 董事候选人屈云庆列席会议。会议召开符合《中华人民共和国公司法》（以下简 称"《公司法》"）《中华人民共和国证券法》（以下简称"《证券法》"）等 有关法律、法规、规章和《公司章程》的规定。 证券代码：301337 证券简称：亚华电子 公告编号：2025-026 山东亚华电子股份有限公司 第四届董事会第四次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 二、董事会会议审议情况 经各位董事认真审议，会议形成了如下决议： （一）审议通过《关于变更经营范围、修订<公司章程>及其附件并 ...

亚华电子（301337）公告，公司董事、副总经理宋庆，董事唐泽远，董事会秘书、财务总监于雷的股份 减持计划期限已届满。宋庆持有公司股份37.26万股，占总股本0.36%；唐泽远持有公司股份19万股，占 总股本0.18%；于雷持有公司股份10万股，占总股本0.10%。上述人员均未减持其所持有的公司股份。 ...

证券代码：301337 证券简称：亚华电子 公告编号：2025-025 山东亚华电子股份有限公司 关于部分董事、高级管理人员股份减持计划期限届满 2、股东本次减持前后持股情况 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 山东亚华电子股份有限公司（以下简称"公司"）于 2025 年 3 月 12 日披露 了《关于部分董事、高级管理人员减持股份的预披露公告》（公告编号：2025- 008）。公司董事、副总经理宋庆计划在减持计划公告之日起十五个交易日后的 三个月内（即 2025 年 4 月 3 日至 2025 年 7 月 2 日期间，在此期间如遇法律法规 规定的窗口期则不减持）以集中竞价或大宗交易方式减持公司股份不超过 90,000 股（占公司总股本比例 0.09%）。公司董事唐泽远计划在减持计划公告之日起十 五个交易日后的三个月内（即 2025 年 4 月 3 日至 2025 年 7 月 2 日期间，在此期 间如遇法律法规规定的窗口期则不减持）以集中竞价或大宗交易方式减持公司股 份不超过 40,000 股（占公司总股本比例 0.04%）。公司董事会秘书、财务总监于 雷计划在减持计划公告之日 ...

Group 1 - The company reported a revenue of 39.57 million yuan for Q1 2025, representing a year-on-year increase of 30.01% [1] - The net profit attributable to shareholders was -5.94 million yuan, an improvement from -8.25 million yuan in the same period last year [1] - The net cash flow from operating activities was -9.83 million yuan, compared to -28.37 million yuan in the previous year [1] Group 2 - In 2024, the company achieved a revenue of 218 million yuan, a decline of 37.97% year-on-year [1] - The net profit attributable to shareholders for 2024 was -26.49 million yuan, down from a profit of 45.52 million yuan the previous year [1] - The company went public on May 26, 2023, with an initial stock price of 32.60 yuan per share, and is currently trading below its initial offering price [1] Group 3 - The total amount raised from the initial public offering was 849.23 million yuan, with a net amount of 765.76 million yuan after deducting issuance costs [2] - The final net amount raised exceeded the original plan by 446.91 million yuan [2] - The company plans to use the raised funds for upgrading its smart medical information platform, building a research center, developing a marketing network, and supplementing working capital [2]

山东亚华电子股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 山东亚华电子股份有限公司（以下简称"公司"）于2025年4月19日在巨潮资讯网 （http://www.cninfo.com.cn）上披露了《2024年年度报告》（公告编号：2025-012）， 经自查发现《2024年年度报告》中"'第四节 公司治理'之'七、董事、监事和高级 管理人员情况'之'2、任职情况''3、董事、监事、高级管理人员报酬情况'"及 "'第四节 公司治理'之'十一、公司员工情况'之'2、薪酬政策'"中的非财务部 分内容有误，现对该部分内容予以更正，相关更正信息不影响公司报告期财务状况、 经营成果和现金流状况。具体更正如下： 一、《2024年年度报告》"第四节 公司治理"之"七、董事、监事和高级管理人 证券代码：301337 证券简称：亚华电子 公告编号：2025-024 员情况"之"2、任职情况"中： 更正前： "李新蕾，女，1982年7月出生，中国国籍，无境外永久居留权，本科学历。历任淄博亚华电子有限公司 研发内勤； 山东金网通信发展有限公司大客户经理；亚华电子办公 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 山东亚华电子股份有限公司（以下简称"公司"）于2025年4月19日在巨潮资讯网 （http://www.cninfo.com.cn）上披露了《2024年年度报告》（公告编号：2025-012）， 经自查发现《2024年年度报告》中"'第四节 公司治理'之'七、董事、监事和高级 管理人员情况'之'2、任职情况''3、董事、监事、高级管理人员报酬情况'"及 "'第四节 公司治理'之'十一、公司员工情况'之'2、薪酬政策'"中的非财务部 分内容有误，现对该部分内容予以更正，相关更正信息不影响公司报告期财务状况、 经营成果和现金流状况。具体更正如下： 证券代码：301337 证券简称：亚华电子 公告编号：2025-024 山东亚华电子股份有限公司 关于对2024年年度报告的补充更正公告 更正前： 在其他单位任职情况 适用 □不适用 | 任职人员姓名 | 其他单位名称 青岛白泽亚华科 | 在其他单位担任 的职务 执行董事兼总经 | 任期起始日期 | 任期终止日期 | 在其他单位是否 领取报酬津贴 | | --- | --- ...

Financial Performance - The net profit attributable to shareholders for the reporting period was -26,486,052.99 RMB, a decrease of 158.19% compared to the same period last year[4]. - The company's operating revenue for 2024 was ¥217,910,015.34, a decrease of 37.97% compared to ¥351,310,084.13 in 2023[23]. - The net profit attributable to shareholders for 2024 was -¥26,486,052.99, representing a decline of 158.19% from ¥45,516,763.94 in 2023[23]. - The net cash flow from operating activities for 2024 was -¥50,334,778.04, a significant decrease of 531.51% compared to -¥7,970,508.38 in 2023[23]. - The basic earnings per share for 2024 was -¥0.25, down 151.02% from ¥0.49 in 2023[23]. - Total assets at the end of 2024 were ¥1,223,315,775.74, a decrease of 5.37% from ¥1,292,728,742.95 at the end of 2023[23]. - The net assets attributable to shareholders at the end of 2024 were ¥1,102,557,347.73, down 3.90% from ¥1,147,259,504.01 at the end of 2023[23]. - Total revenue for 2024 was ¥217,910,015.34, a decrease of 37.97% compared to ¥351,310,084.13 in 2023[88]. - Revenue from hospital intelligent communication systems was ¥215,745,562.86, down 38.40% from ¥350,237,733.77 in the previous year[88]. - The domestic market contributed ¥211,207,767.02, representing 96.92% of total revenue, a decline of 39.22% year-over-year[88]. - The overseas market saw an increase of 76.79%, generating ¥6,702,248.32 compared to ¥3,791,176.74 in 2023[88]. - Gross profit margin for hospital intelligent communication systems was 38.89%, down 6.94% from the previous year[92]. Market Strategy and Expansion - The company aims to consolidate its domestic market while actively investing in overseas market expansion to explore new growth opportunities[4]. - The company plans to maintain investment in new technologies to enhance product competitiveness and seize opportunities in the medical field for renovation projects[4]. - The company is focusing on integrating mobile nursing products with smart ward systems to enhance product competitiveness and increase main revenue[102]. - The company is advancing the development of a new generation of surgical behavior management products based on existing project experience to improve competitiveness in the market[103]. - The company is positioned to benefit from government policies promoting the integration of new generation information technology in elderly care, with plans to establish over 100 standard-compliant smart nursing homes in Shandong Province by the end of 2025[37]. - The company is actively involved in the development of smart hospital solutions, including smart wards and smart outpatient services, which enhance medical resource utilization and management efficiency[35]. - The company is focusing on strategic planning, market expansion, product development, and internal control to adapt to global economic changes and industry competition[145]. Research and Development - The company is focusing on the integration of artificial intelligence, big data, and cloud computing in its operations to improve efficiency and service quality in the healthcare sector[37]. - The company plans to increase R&D investment to create integrated solutions that enhance clinical and management value in hospitals[74]. - R&D investment as a percentage of operating revenue increased to 18.92% in 2024 from 13.48% in 2023[103]. - The number of R&D personnel decreased by 16.41% to 163 in 2024 from 195 in 2023[103]. - The company has accumulated a total of 153 authorized patents and 242 software copyrights as of December 31, 2024, reflecting its commitment to innovation and technology advancement[71]. - The company emphasizes technological innovation, having developed core technologies such as modular nursing communication control technology and high-bandwidth networking solutions[42]. Operational Challenges - The company is facing intensified industry competition and delayed market demand release, impacting revenue expectations[4]. - The main products are experiencing a downward trend in market prices, leading to a decline in overall gross profit margin[4]. - The company acknowledges the risks associated with future plans and encourages investors to be aware of these risks[5]. - The company has not identified any significant risks to its ongoing operations as of the report date[4]. - The company faces seasonal risks due to the nature of hospital procurement processes, which may lead to uneven revenue distribution throughout the year[144]. Governance and Management - The company has established a governance structure in compliance with relevant laws and regulations, ensuring independent operations from its controlling shareholder[151][159]. - The board of directors consists of 9 members, including 3 independent directors, and has held 6 meetings during the reporting period[153]. - The company has implemented a performance evaluation system for senior management that combines quantitative and qualitative assessments, linking compensation to responsibilities and contributions[156]. - The company maintains effective communication with stakeholders, emphasizing social responsibility and balancing interests among various parties[157]. - The company is committed to enhancing its internal control management and improving the overall quality of its management team[145]. Investment and Funding - The company has raised a total of CNY 84,923.00 million through its public offering, with a net amount of CNY 78,253.78 million after deducting fees[122]. - As of December 31, 2024, the company has utilized CNY 38,113.21 million of the raised funds, with CNY 40,069.02 million remaining unutilized[122]. - The company has allocated CNY 25,800 million of the raised funds to permanently supplement working capital and CNY 1,000 million to repay bank loans[122]. - The company has reported a total investment of CNY 3,922,613.75 during the reporting period, marking a 100% increase compared to the previous year[117]. - The company has not reported any issues or problems regarding the use and disclosure of raised funds[125]. Employee and Training - The total number of employees at the end of the reporting period is 604, with 509 in the parent company and 95 in major subsidiaries[189]. - The company organized over 10 large training events in 2024, with more than 300 employees participating, significantly enhancing team skills and corporate culture awareness[192]. - The company provides a comprehensive benefits package, including holiday bonuses, regular health check-ups, commercial insurance, mutual aid funds, and birthday care[191]. - The company has a competitive salary standard based on industry levels, company performance, job value, and regional differences[191]. Profit Distribution Policy - The company emphasizes cash dividends as the primary form of profit distribution, ensuring a minimum of 10% of the distributable profit is allocated as cash dividends[197]. - The cumulative cash dividends over the three-year planning period should not be less than 30% of the average annual distributable profit[197]. - In mature stages without major capital expenditures, the cash dividend proportion should be at least 80% of the profit distribution[200]. - In growth stages with major capital expenditures, the cash dividend proportion should be at least 20%[200]. - The company allows shareholders, independent directors, and public investors to propose suggestions and supervise the dividend policy[198].

Market Performance - The Shanghai Composite Index and Shenzhen Component Index experienced declines of 0.30% and 0.69% respectively on May 5, 2025, while the ChiNext Index and STAR Market 50 fell by 0.87% and 1.96% respectively [1] - Among 33 A-share companies in Zibo, 30 saw an increase, 1 remained flat, and 2 declined during the same period [1] Notable Stock Movements - Weiming Pharmaceutical (002581) achieved a remarkable 23.29% increase over five days, leading the gains [1] - Yahua Electronics (301337) and Jincheng Pharmaceutical (300233) also saw significant increases of 17.30% and 11.31% respectively [1] - On May 7, PEEK material concept stocks surged, with Zhongxin Fluorine Materials (002915) hitting the daily limit for the sixth time in nine days, and Kaisheng New Materials (301069) rising by 2.29% with a trading volume of 4.02 billion yuan [1] Company Announcements - Kehui Co., Ltd. announced a share repurchase plan with a budget between 9 million and 16 million yuan, with a maximum repurchase price of 17 yuan per share, aimed at employee stock ownership plans [1] Financial Results - Furuida (600223) reported a revenue of 526 million yuan in its cosmetics segment for Q1 2025, with a gross margin of 61.06% [3] - Qichang Tenda (002408) achieved total revenue of 5.618 billion yuan in Q1 2025, a year-on-year increase of 2.53%, but saw a significant drop in net profit by 83.18% to 5.4007 million yuan [3] - Xinhua Medical (600587) reported a total revenue of 2.308 billion yuan, down 8.74% year-on-year, with a net profit decline of 23.97% to 160 million yuan [3] - Bohui Paper (600966) reported a total revenue of 4.564 billion yuan, a 3.77% increase year-on-year, but a net profit decline of 46.91% to 53.3737 million yuan [3] Market Capitalization - In terms of market capitalization, Yingke Medical (300677) led with 14.708 billion yuan, followed closely by Shandong Pharmaceutical Glass (600529) at 14.626 billion yuan, and Qichang Tenda (002408) at 12.963 billion yuan [4]

北京德和衡律师事务所 BEIJING DHH LAW FIRM 北京德和衡律师事务所 关于山东亚华电子股份有限公司 2024年年度股东大会的 法律意见书 德和衡证见意见（2025）第67号 中国·北京市朝阳区建国门外大街 2 号银泰中心 C 座 11、12 层 电话： (+86 10) 8540 7666 邮编：100022 www.deheheng.com 北京德和衡律师事务所 关于山东亚华电子股份有限公司 2024年年度股东大会的 法律意见书 德和衡证见意见（2025）第67号 本法律意见书仅供贵公司为本次股东大会之目的而使用，不得用于其他任何目的。本所律 师同意贵公司将本法律意见书随贵公司本次股东大会其他信息披露材料一并向公众披露，并依 法对本法律意见书承担相应责任。 本所律师根据对事实的了解以及对中国现行法律、法规和规范性文件的理解，按照律师行 业公认的业务标准、道德规范和勤勉尽责精神，现出具法律意见如下： 一、 本次股东大会的召集与召开程序 致：山东亚华电子股份有限公司 北京德和衡律师事务所（以下简称"本所"）接受山东亚华电子股份有限公司（以下简称 "公司"或"贵公司"）的委托，指派本所律师出席贵公 ...